Patent classifications
A61K38/1748
INJECTABLE COMPOSITION FOR PREVENTING HAIR LOSS OR STIMULATING HAIR GROWTH
The present invention relates to an injectable pharmaceutical composition containing keratin for preventing hair loss or stimulating hair growth, wherein the composition is excellent in hair follicle generating and hair growth stimulating effects, and thus can be favorably used as a preventive and therapeutic agent for hair loss or a stimulating agent for hair growth.
METHODS OF DELIVERING TRANSGENES TO THE EYE
The present disclosure relates, in part, to methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of transgene expression in the eye. The present disclosure also relates, in part, to methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.
COMPOSITION FOR IMPROVING HAIR HEALTH
A composition comprising two peptides with a size of 11 and 12 amino acids, wherein 2-3 of said amino acids are cysteines and a suitable dermatology excipient, which can be used for treatment and grooming products for animal hair, preferably for treatment and cosmetics for human hair.
Composition for improving hair health
A composition comprising two peptides with a size of 11 and 12 amino acids, wherein 2-3 of said amino acids are cysteines and a suitable dermatology excipient, which can be used for treatment and grooming products for animal hair, preferably for treatment and cosmetics for human hair.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Composition for boosting the immune system
There is provided herein a composition for improving one or more health conditions comprising at least one keratin compound and beta-lactoglobulin (LGB) in a ratio of 1:1 to 1:5.
Composition for boosting the immune system
There is provided herein a composition for improving one or more health conditions comprising at least one keratin compound and beta-lactoglobulin (LGB) in a ratio of 1:1 to 1:5.
Compositions and methods for improving skin quality
Provided herein are methods for improving skin quality in a subject comprising administering to the skin a pharmaceutical composition comprising a polypeptide covalently bound to a hydrophilic polymer and/or a polysaccharide covalently bound to a hydrophilic polymer.
Functional Targeted Brain Endoskeletonization
Compositions and methods are provided for TEMPEST (Target-Element Modification by Physical and Enduring Structural Transmutation), a method for creating durable structures in vivo in a cell-type and/or circuit specific manner via the use of insoluble polymers. TEMPEST provides a way to functionally remove cells while preserving their shadow for easy post-experiment detection and classification. The method of the invention are of particular interest for modifying neurons, which may be central nervous system or peripheral nervous system cells, however the approach may be applied to other cellular systems as well, either in culture system models or in animals.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.